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Introduction
Measurements of apolipoproteins A-I and B are of
growing interest in the clinical and research laboratory
because levels of these proteins in the blood have been
shown to serve as important predictors of atherosclerotic
vascular disease, and they provide information not
available from total cholesterol or lipoprotein cholesterol
levels. Apolipoprotein A-I and B measurements have not
reached their full potential in the clinical laboratory
because of inadequate standardization and problems in
methodology. Although both polyclonal and monoclonal
antibodies have been used extensively in apolipoprotein
assays, monoclonal antibodies offer the advantages of
being chemically uniform, providing high specificity, and
they can be produced in large amounts. As a result, more
and more researchers and manufacturers have turned to
monoclonal antibodies for the development of apolipo-
protein immunoassays. However, generating and select-
ing monoclonal antibodies that are appropriate for the
measurement of apolipoproteins A-I and B are difficult
and time-consuming. On the other hand, an inadequate
characterization of the monoclonal antibodies can lead to
technical artefacts and to no comparability ofthe data. In
order to facilitate the appropriate use of monoclonal
antibodies in the measurement of apo A-I and B, some
important considerations for generating and selecting
suitable monoclonal antibodies have been outlined by the
IFCC’s Committee on Apolipoproteins.
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Many of the problems encountered in the immunoassays
can be related directly to the physical and chemical
properties peculiar to lipoproteins, and they can be
particularly important when monoclonal antibodies are
used. In contrast to other plasma proteins, lipoproteins
are compelx non-covalent associations of multiple lipids
and proteins. Some of the apolipoprotein antigenic
determinants can be concealed by the complex protein/
lipid and protein/protein interactions that occur in native
lipoproteins. Even when the lipoproteins are delipidated
and the apolipoproteins isolated, antigenic determinants
still can be masked because the delipidated apolipopro-
teins readily aggregate in aqueous buffers.
Conformational differences between purified apo A-I and
apo A-I in native lipoproteins may account for significant
differences in the expression of apo A-I antigenic
determinants. A further complication has been described,
which is related to the specific non-enzymatic modifica-
tion of apo A-I [1,2]. This modification, which can
include deamination of asparagine and glutamine resi-
dues during storage and perhaps also in vivo, can interfere
with the binding of specific monoclonal antibodies.
In addition to the above-mentioned difficulties in the
selection and characterization of monoclonal antibodies
for measuring apolipoproteins, all monoclonal reagents
have other peculiar properties, all monoclonal reagents
have other peculiar properties that require careful
consideration ofspecific assay parameters. Some monclo-
nal antibodies can be remarkably sensitive to detergents,
the pH or ionic strength of the buffers and the tempera-
ture of the reaction mixture. Therefore, these assay
parameters need to be established and carefully followed.
Researchers and manufacturers are therefore recom-
mended to clearly indicate the immunochemical charac-
teristics of the monoclonal antibodies selected for the
immunoassays.
Generation and selection of monoclonal antibodies
Because of the unique characteristics of apolipoproteins
as antigens in immunoassays, this document makes
specific recommendations for generating and selecting
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the best monoclonal antibodies for use, and for character-
izing the selected antibodies. The best antibodies will
usually be of high affinity. Therefore, to select high
affinity monoclonal antibodies, the following procedures
are recommended. First, classic immunologic dogma has
demonstrated that multiple injections of low doses of
antigen (10-50 tg ofprotein) over long period oftime will
result in the generation in vivo of a limited repertoire of
antibodies of highest affinity. Therefore, a minimum of
four intraperitoneal immunizations is recommended at
2 week intervals. The antigen can also be injected at
several sites by subcutaneous or intradermal routes. If
time permits, more immunizations over longer periods of
time with larger intervals between injections are pre-
ferred. The use of adjuvants will in most cases improve
the response. Second, because it is desirable to amplify in
vivo only those plasmacells which produce immunoglobu-
lin of the highest affinity, the intravenous injections given
on days -4, -3, and -2 before fusion should contain
only low doses ofantigen, preferably one-third to one-half
of the intraperitoneal dose. It is advisable to screen the
serum of the immunized mice for reactivity against the
immunizing antigen, in order to select for boosting the
mouse with the highest antibody titre. It is usual to try to
reach a titre (inverse ofserum dilution at which the signal
in the assay is decreased by 50%) no less than 104
However, even though the serum titre elicited has
undoubted relevance, it should be noted that a good titre
after the preimmunization period is not a sufficient
condition for a high specific efficiency. This is more
dependent on an adequate final immunization protocol.
Third, either purified apolipoprotein or isolated lipopro-
tein can be used for immunization. However, to ensure
that the antibodies selected are capable of identifying the
native lipoprotein, the hybridomas must be screened after
fusion for their capacity to produce antibodies that bind
the native lipoprotein. Only freshly prepared antigens
should be used for immunization and screening. Fourth,
to select only those antibodies that are capable ofbinding
antigen at low concentrations, the hybridomas should
always be screened at high dilution. Dilutions of the
culture supernantants of 1:100 or higher are preferred,
although, in this situation, a low concentration of high
affinity antibody could be missed. Fifth, a secondary
screen should be performed on all antibodies to assess
their capacity to bind antigen in solution, as well as
antigen bound to a solid-phase matrix. This assay can
take a number offormats, including immobilization ofthe
antibody or classical double antibody fluid-phase im-
munoassay using radioiodinated LDL or HDL. The
format that is ultimately to be used for the immunoassay
should also be used as the secondary screening step.
Sixth, because IgG antibodies generally are preferable for
use in immunoassays, screening for specific immuno-
globulin heavy chains can be useful. A number of kits for
identifying the mouse immunoglobulin heavy chain types
are available.
the presence of contaminants in the antigen preparation
used for immunization, and the unwanted specificities
were eliminated by immunoadsorption. However, totally
unexpected cross-reactivities between apparently unre-
lated molecules have been detected with monoclonal
antibodies to several proteins [3]. A series of proteins
which show immunological cross-reactivity with human
apo D also have been identified [4]. Presumably these
antibodies exist in different amounts in polyclonal
antisera and can be responsible for the lack of specificity.
The most common criteria for assuring the specificity of
antibodies against apolipoproteins is to verify that the
antibodies react with the apolipoprotein in question and
not with other purified apolipoproteins. In general these
studies are performed by direct or competitive enzyme
immunoassay or radioimmunoassay. These tests, how-
ever, do not exclude cross-reactivities with other mol-
ecules in plasma. To document that the monoclonal
antibodies are specific for one apolipoprotein, the most
discriminating test, one or two-dimensional Western
immunoblotting [5-7], is recommended. Electro-
phoretically separated proteins are transferred to a
nitrocellulose sheet for reaction with dilutions of anti-
body. Monoclonal antibody binding is detected by a
second incubation with a radioiodinated second antibody
(usually rabbit or goat anti-mouse Ig) followed by
autoradiography. Enzyme conjugated anti-mouse Ig, and
the appropriate substrates for colour development, can
also be used. To document the lack of cross-reactivity
with other apolipoproteins and plasma components not
associated with lipoproteins, monoclonal antibodies
should be tested by Western immunoblotting against the
apolipoproteins of isolated lipoproteins and whole
plasma. However, it needs to be underlined that the SDS
Page step prior to Western blotting is denaturing and,
therefore, some clinically useful monoclonal antibodies
reacting only with nondenatured antigenic determinants
could fail to be detected by immunoblotting. Monoclonal
antibodies to apo B should also be tested for their
reactivity with apo B-48.
It has long been accepted that, for polyclonal antisera,
specificity can be a function of the sensitivity of the test
used to verify the specificity. Thus, an antisera, deter-
mined to be specific by immunoelectrophoresis (sensiti-
vity in the pg/ml range). This would be expected to be
less of a problem with monoclonal antibodies.
Nevertheless, one might imagine a situation in which
cros-reactivities exist between two native molecules
(which presumably would be detected in a radioim-
munoassay), but not between the denatured molecules
(and thus not detected on Western blots). Therefore, the
specificity of the antibodies should be confirmed in the
assay in which the antibody is to be used.
Affinity constant
Specificity
The problem ofspecificity has always been a critical issue
in the preparation of polyclonal antisera. When found,
the lack of specificity of an antiserum was attributed to
Generally, high affinity monoclonal antibodies are highly
specific and less sensitive to the modifications of the
immunoassay conditions. For these reasons it is import-
ant at the first stage of selection to determine the affinity
constant. The recommended method for determining the
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affinity constant is a competitive fluid-phase radioim-
munoassay. The test is performed by adding increasing
amounts of apolipoprotein or isolated lipoprotein to
compete with a known amount of labelled lipoprotein for
a limited amount of monoclonal antibody. The displace-
ment curves are analysed by Scatchard analysis and the
affinity constant calculated and expressed as litres per
mole [8-10]. A simplified approach for estimating
antibody affinity has been reported by Miiller 11 and it
can be useful in the selection of monoclonal antibodies.
We recommend that the affinity constants of monoclonal
antibodies selected for use in immunoassays should be at
least 109 1/mol.
Recognition of isolated and native apolipoproteins
One of the most common problems found with
apolipoprotein-specific monoclonal antibodies is that
many of the antibodies do not recognize the isolated
delipidated apolipoprotein in the same way as they
recognize the same apolipoprotein in a complex lipopro-
tein [4,5,12]. Furthermore, differences have been
observed between an isolated lipoprotein and that same
lipoprotein in plasma [13]. Therefore, any monoclonal
antibody used for estimating plasma levels ofan apolipo-
protein must be capable of identifying the apolipoprotein
in the sample, in the primary standard and in the
calibrator in exactly the same manner, i.e. with the same
affinity. This requirement is fundamental in competitive
assays, but it is less important in non-competitive assays.
Also, the antibody should detect an epitope that is
expressed on all lipoproteins in which the apolipoprotein
is present, and the affinity for the apolipoprotein should
be independent ofthe physical and chemical properties of
the lipoprotein in which it is found. To document that the
affinity ofthe antibody is the same, all standards, samples
and calibrators must be compared as competitors and the
slopes of the competition curves compared [5]. This is
performed by adding increasing amounts of apolipopro-
tein, isolated lipoprotein or plasma to the immunoassay
in the presence of a limiting amount of antibody. If the
results are plotted on a linear log scale of percentage
binding versus the log of the concentration of the
competitor, the slopes of the linear portions of the curves
can be compared. Additionally, logit transformation of
the binding data will permit an analysis of the slopes of
the competitors over a greater concentration range. In
addition to comparisons of samples, standards and
calibrators in the assay format, it is also important to
establish whether storage ofthe samples or standards will
result in changes in binding affinity.
Immunochemical heterogeneity of apolipoproteins
A major stumbling block to the development of im-
munoassays with monoclonal reagents for total plasma
levels of apo A-I or apo B is the observation that neither
apo A-I or apo B appear to represent immunochemically
homogenous proteins in lipoprotein particles. That is,
many apo B-specific as well as apo A-I-specific monoclo-
nal antibodies have been described that do not bind
100% of LDL or 100% of HDL, respectively [4,5,7,12].
For this reason, careful screening and selection pro-
cedures must be used to select monoclonal antibodies that
bind all of the antigen. A number of procedures can be
adapted for assessing the capacity of a monoclonal
antibody to bind 100% of antigen, and each of these
assays has two properties. The ligand must be labelled
(i.e. LDL or HDL must be isolated and radioiodinated)
and the antibody must be present in excess in the reaction
mixture. There are two recommended methods. First, the
assessment of percentage binding can be examined on
immunoabsorbant columns. Here large amounts of
monoclonal antibody are isolated, coupled to an insoluble
support, and then reacted with a limiting and know
amount of labelled LDL or HDL to document that in
antibody excess, all of the LDL or HDL can be bound by
the antibody. The non-specific absorption of support
must be carefully evaluated. A second approach is to
assess percentage binding of the ligand in fluid-phase
double antibody radioimmunoassays. In this apprsach a
known and limited amount of labelled LDL or HDL is
reacted with increasing concentrations of monoclonal
antibody in a fluid-phase reaction. At equilibrium the
bound radioiodinated lipoprotein is separated from the
unbound lipoprotein by direct precipitation with optimal
amounts of a second antibody, reaction with an excess of
immobilized second antibody, or reaction with protein A.
Correct interpretation of these assays assumes that
labelled and unlabelled lipoprotein ligands behave
immunochemically in an identical manner, and that true
monoclonal antibody excess (relative to antigen) was
obtained. Monoclonal antibodies that do not bind all of
LDL or HDL are generally not appropriate for use in
immunoassays for plasma levels ofapo B and apo A-I. In
this case, a combination of monoclonal antibodies
capable of identifying all LDL or HDL can be used.
However, while this document is devoted to recommen-
dation of monoclonal antibodies for measuring total apo
A-I or apo B, it should be emphasized that individual
monoclonal antibodies that do not bind all of LDL or
HDL could potentially be used to quantify clinically
important subsets of apo A-I- and apo B-containing
lipoproteins.
Recognition of unique epitopes
In some instances it may be important to document that
specific monoclonal antibodies identify unique antigenic
determinants on apo A-I or apo B. If capture assays are
used, it is imperative that the binding of one antibody
does not interfere with the binding of the other. If the
antibodies are used in immunoassays in which immuno-
precipitation is required as a secondary reaction, oligo-
clonal mixtures of the monoclonal antibodies will be
required [7,14]. In some instances it may be useful to
combine monoclonal antibodies into oligoclonal mixtures
in order to increase the apparent affinity of a particular
reaction or to reach 100% of the binding ofLDL or HDL
if a single monoclonal antibody alone will not do so. In
each case the antibodies used must identify unique
epitopes on the apolipoprotein. This can be verified by
performing antibody competition assays. The antibodies
are isolated, radioiodinated, and the capacity of increas-
ing amounts of one unlabelled monoclonal antibody to
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interfere with the binding ofa limited amount ofa second
radioiodinated monoclonal antibody is assessed [15]. If
the binding of the unlabelled antibody is not blocked by
an excess of the first unlabelled antibody, it can be
concluded that the two antibodies identify separate
epitopes on the apolipoprotein.
Polymorphism
A final caution in the characterization of monoclonal
antibodies for use in estimating plasma levels of the
apolipoproteins concerns the recent reports that some
monoclonal antibodies identify genetic polymorphisms in
apo B [16,17]. The monoclonal antibody used in these
studies, MB19, identifies a common genetic polymor-
phism in LDL. This polymorphism is characterized by
the capacity of the MB19 antibody to bind to apo B-100
from different individuals with either high or low affinity.
The possibility exsits that additional genetic polymor-
phisms in apo B, as well as in apo A-I, will be identified
with monoclonal antibodies. Therefore, it must be
established that any monoclonal antibody use for esti-
mating total plasma levels of apo B or apo A-I does not
distinguish a common genetic polymorphism. To do this,
the plasmas of a minimum of 100 unrelated individuals
should be tested and the levels ofapo A-I or B measured
with the monoclonal antibody compared with the levels
obtained by an independent method. Independent
measurements ofapo A-I and apo B can be obtained with
immunoassay procedures employing polyvalent anti-
bodies or other physical chemical estimates of apolipo-
protein mass. If no systematic bias is found, it can be
reasonably concluded that the monoclonal antibodies do
not identify a common apolipoprotein genetic
polymorphism.
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